甲状腺がん治療薬の世界市場レポート 2025年

甲状腺がん治療薬市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR13.0％で22億米ドルに成長します。予測期間の成長は、有病率の増加と高齢化、精密医療の進歩、ヘルスケアインフラ開発、意識の高まり、早期発見に起因します。予測期間の主な動向には、個別化医療、標的治療と免疫療法、臨床試験と医薬品パイプライン、併用療法、バイオマーカー主導型治療、遠隔医療と遠隔モニタリングなどが含まれます。

甲状腺がん治療薬市場は、特に女性における甲状腺がんの罹患率の増加により成長を遂げています。例えば、2022年、米国がん協会は、米国における甲状腺がんの推定新規症例数約43,800例を報告し、その内訳は女性31,940例、男性11,860例で、甲状腺がんによる死亡者数は2,230人でした。これらの死亡者のうち、1,070人が男性、1,160人が女性です。このような甲状腺がん、特に女性の甲状腺がん患者の急増が、甲状腺がん治療薬市場成長の原動力となっています。

ヘルスケア支出の増加は、今後数年間の甲状腺がん治療薬市場の成長を促進すると予想されます。ヘルスケア支出とは、特定のヘルスケアシステムや経済圏における、ヘルスケア関連の商品やサービスへの総支出を指します。この支出は、甲状腺がん治療薬の開発、アクセシビリティ、アベイラビリティを支える重要な役割を果たしています。例えば、2022年11月、米国の非営利団体であるCanadian Institute for Health Informationは、ヘルスケア支出は2021年の7.6％から0.8％増加し、2022年には3,310億米ドルに達したと報告しました。その結果、医療費の増加が甲状腺がん治療薬市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界甲状腺がん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の甲状腺がん治療薬市場：成長率分析
• 世界の甲状腺がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の甲状腺がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界甲状腺がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の甲状腺がん治療薬市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• イピリムマブ
• カボザンチニブ-S-マレート
• カプレルサ（バンデタニブ）
• 塩酸ドキソルビシン
• レンバチニブメシル酸塩
• ニボルマブ
• バンデタニブ
• その他の薬物の種類
• 世界の甲状腺がん治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 放射性ヨウ素アブレーション
• 甲状腺刺激ホルモン（TSH）抑制
• 化学療法
• 標的マルチキナーゼ療法
• その他のタイプ
• 世界の甲状腺がん治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 腫瘍学クリニック
• 調査機関
• その他のエンドユーザー
• 世界の甲状腺がん治療薬市場イピリムマブの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• イピリムマブ単剤療法
• イピリムマブとの併用療法
• 世界の甲状腺がん治療薬市場カボザンチニブ-S-マレートのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• カボザンチニブ単剤
• カボザンチニブとの併用療法
• 世界の甲状腺がん治療薬市場カプレルサ（バンデタニブ）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 甲状腺髄様がん（MTC）に対するバンデタニブ
• バンデタニブとの併用療法
• 世界の甲状腺がん治療薬市場塩酸ドキソルビシンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法のためのドキソルビシン
• リポソームドキソルビシン
• 世界の甲状腺がん治療薬市場レンバチニブメシル酸塩の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 分化型甲状腺がん（DTC）に対するレンバチニブ
• レンバチニブとの併用療法
• 世界の甲状腺がん治療薬市場ニボルマブの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ニボルマブ単剤療法
• ニボルマブとの併用療法
• 世界の甲状腺がん治療薬市場バンデタニブの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• バンデタニブ単剤
• バンデタニブとの併用療法
• 世界の甲状腺がん治療薬市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ソラフェニブ
• エベロリムス
• ペンブロリズマブ

第7章 地域別・国別分析

• 世界の甲状腺がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の甲状腺がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 甲状腺がん治療薬市場：競合情勢
• 甲状腺がん治療薬市場：企業プロファイル
  • Mylan Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Alara Pharmaceutical Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • APP Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• GlaxoSmithKline plc
• Exelixis Inc.
• Novartis AG
• Pfizer Inc.
• Biovista Inc.
• Vascular Biogenics Ltd.
• Azaya Therapeutics Inc.
• Bionomics Limited
• Bayer AG
• Eisai Co. Ltd.
• Bio-Path Holdings Inc.
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Bristol-Myers Squibb Company

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 甲状腺がん治療薬市場2029：新たな機会を提供する国
• 甲状腺がん治療薬市場2029：新たな機会を提供するセグメント
• 甲状腺がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Thyroid cancer drugs are pharmaceutical agents utilized in the treatment of thyroid cancer. These drugs work by inhibiting various kinase proteins, primarily by preventing the formation of new blood vessels that cancer cells require for growth. They target specific proteins that cancer cells often produce to facilitate their growth. Thyroid cancer typically originates in the thyroid tissue, composed of follicular cells and parafollicular cells.

The main categories of thyroid cancer drugs include radioiodine ablation, thyroid stimulating hormone (TSH) suppression, chemotherapy, targeted multikinase therapy, and other therapeutic approaches. Radioiodine ablation is a form of radiation therapy that employs radioactive iodine to eliminate or ablate any remaining healthy thyroid tissue following a thyroidectomy. Various drugs are used in the treatment of thyroid cancer, including ipilimumab, cabozantinib-s-malate, caprelsa (vandetanib), doxorubicin hydrochloride, lenvatinib mesylate, nivolumab, vandetanib, and others. These drugs find applications in sectors such as hospitals, oncology clinics, research organizations, and others as part of thyroid cancer treatment.

The thyroid cancer drugs market research report is one of a series of new reports from The Business Research Company that provides thyroid cancer drugs market statistics, including thyroid cancer drugs industry global market size, regional shares, competitors with a thyroid cancer drugs market share, detailed thyroid cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the thyroid cancer drugs industry. This thyroid cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The thyroid cancer drugs market size has grown rapidly in recent years. It will grow from $1.17 billion in 2024 to $1.35 billion in 2025 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to increasing incidence of thyroid cancer, advances in medical research, favorable regulatory environment, growing healthcare expenditure.

The thyroid cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $2.2 billion in 2029 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to increasing prevalence and aging population, advancements in precision medicine, healthcare infrastructure development, rising awareness and early detection. Major trends in the forecast period include personalized medicine, targeted therapies and immunotherapies, clinical trials and drug pipeline, combination therapies, biomarker-driven treatments, telemedicine and remote monitoring.

The thyroid cancer drugs market is experiencing growth due to the increasing incidences of thyroid cancer, especially in women. For example, in 2022, The American Cancer Society reported approximately 43,800 estimated new cases of thyroid cancer in the United States, with 31,940 cases in women and 11,860 cases in men, leading to 2,230 deaths from thyroid cancer. Among these fatalities, 1,070 are men, and 1,160 are women. This surge in thyroid cancer cases, particularly among women, is a driving force behind the growth of the thyroid cancer drugs market.

The increasing healthcare expenditure is expected to drive the growth of the thyroid cancer drugs market in the coming years. Healthcare expenditure refers to the total spending on healthcare-related goods and services within a specific healthcare system or economy. This expenditure plays a vital role in supporting the development, accessibility, and availability of thyroid cancer drugs. For example, in November 2022, the Canadian Institute for Health Information, a US-based non-profit organization, reported that healthcare spending increased by 0.8%, reaching $331 billion in 2022, compared to 7.6% in 2021. As a result, the rise in healthcare expenditure is fueling the expansion of the thyroid cancer drugs market.

The use of combination drugs in thyroid cancer treatment is growing due to their effectiveness in preventing cancer progression. Combination drugs consist of two or more active pharmaceutical ingredients (APIs) in a single dosage form. These drugs help reduce the development of drug resistance and inhibit the growth of cancer cells. For instance, the FDA approved the combination of dabrafenib (Tafinlar), a BRAF inhibitor, and trametinib (Mekinist), a MEK inhibitor for the treatment of anaplastic thyroid cancer.

Leading companies in the thyroid cancer market are developing innovative products like selpercatinib to enhance treatment options and outcomes for patients. Selpercatinib, sold under the brand name Retevmo, is a medication used to treat various cancers linked to Rearranged During Transfection (RET) mutations, including advanced or metastatic medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. For example, in September 2024, Eli Lilly and Company, a US-based pharmaceutical firm, received approval from the U.S. Food and Drug Administration (FDA) for selpercatinib (Retevmo) to treat advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation. This approval applies to both adult and pediatric patients aged 2 years and older who require systemic therapy. This recent approval represents a significant advancement in treatment options for patients with this specific form of thyroid cancer.

In August 2022, Bristol Myers Squibb, a U.S.-based pharmaceutical company, acquired Turning Point Therapeutics for an undisclosed amount. This strategic acquisition expands BMS's portfolio, particularly in the development of precision medicine for cancer patients, including thyroid cancer drugs.

Major companies operating in the thyroid cancer drugs market include Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Baxter International Inc., Abbott Laboratories, APP Pharmaceuticals LLC, AstraZeneca PLC, GlaxoSmithKline PLC, Exelixis Inc., Novartis AG, Pfizer Inc., Biovista Inc., Vascular Biogenics Ltd., Azaya Therapeutics Inc., Bionomics Limited, Bayer AG, Eisai Co. Ltd., Bio-Path Holdings Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company), Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Hikma Pharmaceuticals PLC, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Sanofi S.A., Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Gilead Sciences Inc., Grifols S.A., Jazz Pharmaceuticals PLC, Mallinckrodt Pharmaceuticals (a subsidiary of Specialty Generics Holdings), Medtronic PLC, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd.

North America was the largest region in the thyroid cancer drugs market in 20242. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the thyroid cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The thyroid cancer drugs market consists of sales cabozantinib-s-malate, caprelsa, and cometriq. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Thyroid Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on thyroid cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for thyroid cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The thyroid cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Ipilimumab; Cabozantinib-S-Malate; Caprelsa (Vandetanib); Doxorubicin Hydrochloride; Lenvatinib Mesylate; Nivolumab; Vandetanib; Other Drug Types
• 2) By Type: Radioiodine Ablation; Thyroid Stimulating Hormone (THS) Suppression; Chemotherapy; Targeted Multikinase Therapy; Other Types
• 3) By End Users: Hospitals; Oncology Clinics; Research Organizations; Other End-Users
• Subsegments:
• 1) By Ipilimumab: Monotherapy Ipilimumab; Combination Therapy With Ipilimumab
• 2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib; Combination Therapy With Cabozantinib
• 3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC); Combination Therapy With Vandetanib
• 4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy; Liposomal Doxorubicin
• 5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC); Combination Therapy With Lenvatinib
• 6) By Nivolumab: Monotherapy Nivolumab; Combination Therapy With Nivolumab
• 7) By Vandetanib: Single-Agent Vandetanib; Combination Therapy With Vandetanib
• 8) By Other Drug Types: Sorafenib; Everolimus; Pembrolizumab
• Companies Mentioned: Mylan Pharmaceuticals Inc.; Alara Pharmaceutical Corporation; Baxter International Inc.; Abbott Laboratories; APP Pharmaceuticals LLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Thyroid Cancer Drugs Market Characteristics

3. Thyroid Cancer Drugs Market Trends And Strategies

4. Thyroid Cancer Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Thyroid Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Thyroid Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Thyroid Cancer Drugs Market Growth Rate Analysis
• 5.4. Global Thyroid Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Thyroid Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Thyroid Cancer Drugs Total Addressable Market (TAM)

6. Thyroid Cancer Drugs Market Segmentation

• 6.1. Global Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ipilimumab
• Cabozantinib-S-Malate
• Caprelsa (Vandetanib)
• Doxorubicin Hydrochloride
• Lenvatinib Mesylate
• Nivolumab
• Vandetanib
• Other Drug Types
• 6.2. Global Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radioiodine Ablation
• Thyroid Stimulating Hormone (TSH) Suppression
• Chemotherapy
• Targeted Multikinase Therapy
• Other Types
• 6.3. Global Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Oncology Clinics
• Research Organizations
• Other End-Users
• 6.4. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Ipilimumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy Ipilimumab
• Combination Therapy With Ipilimumab
• 6.5. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Cabozantinib-S-Malate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Agent Cabozantinib
• Combination Therapy With Cabozantinib
• 6.6. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Caprelsa (Vandetanib), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vandetanib For Medullary Thyroid Cancer (MTC)
• Combination Therapy With Vandetanib
• 6.7. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Doxorubicin Hydrochloride, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Doxorubicin For Chemotherapy
• Liposomal Doxorubicin
• 6.8. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Lenvatinib Mesylate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lenvatinib For Differentiated Thyroid Cancer (DTC)
• Combination Therapy With Lenvatinib
• 6.9. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Nivolumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy Nivolumab
• Combination Therapy With Nivolumab
• 6.10. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Vandetanib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Agent Vandetanib
• Combination Therapy With Vandetanib
• 6.11. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sorafenib
• Everolimus
• Pembrolizumab

7. Thyroid Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Thyroid Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Thyroid Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Thyroid Cancer Drugs Market

• 8.1. Asia-Pacific Thyroid Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Thyroid Cancer Drugs Market

• 9.1. China Thyroid Cancer Drugs Market Overview
• 9.2. China Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Thyroid Cancer Drugs Market

• 10.1. India Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Thyroid Cancer Drugs Market

• 11.1. Japan Thyroid Cancer Drugs Market Overview
• 11.2. Japan Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Thyroid Cancer Drugs Market

• 12.1. Australia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Thyroid Cancer Drugs Market

• 13.1. Indonesia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Thyroid Cancer Drugs Market

• 14.1. South Korea Thyroid Cancer Drugs Market Overview
• 14.2. South Korea Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Thyroid Cancer Drugs Market

• 15.1. Western Europe Thyroid Cancer Drugs Market Overview
• 15.2. Western Europe Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Thyroid Cancer Drugs Market

• 16.1. UK Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Thyroid Cancer Drugs Market

• 17.1. Germany Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Thyroid Cancer Drugs Market

• 18.1. France Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Thyroid Cancer Drugs Market

• 19.1. Italy Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Thyroid Cancer Drugs Market

• 20.1. Spain Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Thyroid Cancer Drugs Market

• 21.1. Eastern Europe Thyroid Cancer Drugs Market Overview
• 21.2. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Thyroid Cancer Drugs Market

• 22.1. Russia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Thyroid Cancer Drugs Market

• 23.1. North America Thyroid Cancer Drugs Market Overview
• 23.2. North America Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Thyroid Cancer Drugs Market

• 24.1. USA Thyroid Cancer Drugs Market Overview
• 24.2. USA Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Thyroid Cancer Drugs Market

• 25.1. Canada Thyroid Cancer Drugs Market Overview
• 25.2. Canada Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Thyroid Cancer Drugs Market

• 26.1. South America Thyroid Cancer Drugs Market Overview
• 26.2. South America Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Thyroid Cancer Drugs Market

• 27.1. Brazil Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Thyroid Cancer Drugs Market

• 28.1. Middle East Thyroid Cancer Drugs Market Overview
• 28.2. Middle East Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Thyroid Cancer Drugs Market

• 29.1. Africa Thyroid Cancer Drugs Market Overview
• 29.2. Africa Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Thyroid Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Thyroid Cancer Drugs Market Competitive Landscape
• 30.2. Thyroid Cancer Drugs Market Company Profiles
  • 30.2.1. Mylan Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Alara Pharmaceutical Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. APP Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis

31. Thyroid Cancer Drugs Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. GlaxoSmithKline plc
• 31.3. Exelixis Inc.
• 31.4. Novartis AG
• 31.5. Pfizer Inc.
• 31.6. Biovista Inc.
• 31.7. Vascular Biogenics Ltd.
• 31.8. Azaya Therapeutics Inc.
• 31.9. Bionomics Limited
• 31.10. Bayer AG
• 31.11. Eisai Co. Ltd.
• 31.12. Bio-Path Holdings Inc.
• 31.13. Takeda Pharmaceutical Company Limited
• 31.14. AbbVie Inc.
• 31.15. Bristol-Myers Squibb Company

32. Global Thyroid Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Thyroid Cancer Drugs Market

34. Recent Developments In The Thyroid Cancer Drugs Market

35. Thyroid Cancer Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Thyroid Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Thyroid Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Thyroid Cancer Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer